CClinicalTrials.gg
RecruitingNCT07158463Updated Sep 5, 2025

Experience With Therapeutic Plasma Exchange in the Pediatric Nephrology Unit of Sohag University Hospital

An observational study in Experience With Therapeutic Plasma Exchange in the Pediatric Nephrology Unit, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Sohag University · Observational

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 1 month later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
25
Ages
1 Year to 18 Years
Sex
All
01

Study summary

Plasmapheresis also known as a therapeutic plasma exchange (TPE) TPE is an extracorporeal blood purification technique designed for the removal of large-molecular-weight substances. Examples of these substances include pathogenic autoantibodies, immune complexes, cryoglobulins, myeloma light chains, endotoxin, and cholesterol-containing lipoproteins Document the indications, procedures, outcomes, and complications associated with TPE in pediatric patients at Sohag University Hospital.

To compare our findings with existing national and international data to identify areas for improvement and standardization.

To evaluate the safety and efficacy of TPE in our pediatric nephrology unit.

02

Conditions studied

  • Experience With Therapeutic Plasma Exchange in the Pediatric Nephrology Unit
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All pediatric patients (aged 1-18 years) who underwent TPE during the study period.

Both male and female.

Inclusion criteria

All pediatric patients (aged 1-18 years) who underwent TPE during the study period.

Both male and female.

Exclusion criteria

Exclusion Criteria:

Patients who cannot tolerate central line placement Patients who are in an actively septic state or are hemodynamically unstable . Patients who have allergies to fresh frozen plasma (FFP) or albumin, depending on the type of plasma exchange

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Efficacy of therapeutic plasma exchange in pediatric nephrology unit

    Time frame: One month after last session

07

Study locations

1 of 1 sites recruiting
  • Faculty of medicine sohag university
    Sohag, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07158463
Lead sponsor
Sohag University
Responsible party
Shohanda Ahmed Mohamed (Resident of pediatrics, Sohag University) — Principal investigator
First posted
Sep 5, 2025
Start date
Aug 15, 2025
Primary completion
Aug 1, 2026 (estimated)
Completion
Aug 15, 2026 (estimated)
Last update
Sep 5, 2025

Study contacts

Shohanda Ahmed Mohamed, Master degree
Contact
shohandaahmed12345@gmail.com
01228288470 ext. 01112966126
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion